The PBAC is now seeking public submissions on a new listing process for ‘pan-tumour’ medicines ahead of a special PBAC meeting that will take place in August.
Submissions must be made in writing and emailed to the PBAC Secretariat. Further information can be found on the August 2018 PBAC special meeting page.
A background paper PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types has also been published and can be accessed here.